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Objective: Heart failure (HF), a long term outcome of chronic methamphetamine use (MU), 
occurs more frequently in racial and ethnic minority populations at high risk for cardiovascular 
disparities. This study examined the association of socio-demographic and clinical risk factors 
with MU among heart failure patients who are Native Hawaiians (NH) or other Paciﬁ  c Island 
peoples (PIP).
Design/Setting/Patient population: Cross-sectional study of NHs and PIPs with advanced 
heart failure enrolled in the Malama Pu’uwai Study, a randomized control trial to test an 
educational intervention to reduce re-hospitalization and/or death. A total of 82 participants were 
enrolled between 6/1/06 to 12/31/07 and met the following eligibility criteria: 1) self-identiﬁ  ed 
NH or PIP, 2) Left ventricular systolic ejection fraction  45%, 3) Age of 21 years or older. 
Data were analyzed by odds ratios (OR), 95% conﬁ  dence intervals (CI), and multiple logistic 
regression analysis.
Main outcome measure: Methamphetamine use.
Results: Twenty-two percent of HF participants were identiﬁ  ed as being current or prior 
methamphetamine users. Younger age and non-married status (combined never married or 
divorced/separated) were independently associated with MU after adjustment for sex, education, 
and other co-morbidities associated with HF (ie, age  50 years, OR = 0.16, 95% CI, 0.03–0.84; 
non-married status combined as never married OR = 8.5, CI, 1.5–47; divorced/separated 
OR = 11, CI 1.8–75).
Conclusions: Risk factors associated with MU in NH and PIPs with heart failure include: 
younger age and being divorced/separated or never married. Health care providers 
should be aware of MU as a contributing factor in the approach and treatment of HF in 
NHs and PIPs.
Keywords: Native Hawaiian and other Paciﬁ  c Islander, ethnic minority, methamphetamine 
use, heart failure
Introduction
Methamphetamine use (MU), initially recognized as a health problem limited to 
Hawai’i and the western region of the US, has continued to spread eastward and has 
increasingly affected both rural and urban areas throughout the US.1 According to a 
2005 national survey, an estimated 10.4 million people age 12 years or older have 
tried the highly addictive drug in the US.2 Minority populations are at higher risk, 
particularly racial/ethnic groups such as Native Hawaiians (NHs) and Paciﬁ  c Island 
Peoples (eg, Samoan, Tongan, Micronesian) who are concentrated in the western 
regions of the US Native Hawaiians experienced a 10-fold increase in methamphet-
amine use between 1995–1998.3,4 In parallel with this upward trend, 5.6% of all Native 
Hawaiian 12th graders in the state of Hawai’i have used methamphetamine at least Vascular Health and Risk Management 2009:5 46
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once in their lifetime compared with 4.8% among high school 
seniors nationally.1,5 In the wake of the growing epidemic 
of MU, health care providers and acute care hospitals 
are seeing long term health effects of methamphetamine 
use.6–9 Between 2004 and 2005, estimated emergency 
department visits for methamphetamine abuse rose by 
almost 50% to 108,905 visits per year.10,11 In addition, 
treatment admissions for methamphetamine abuse also have 
increased to 150,000 admissions per year in 2004 and the 
number of states reporting high rates of admissions (deﬁ  ned 
as  24 per 100,000 population) increased from 5 states in 
1992 to 21 states in 2002.1
Despite the growing and persistent problem of MU, few 
studies have examined long term health problems attributable 
to chronic MU. Although behavioral and neurological effects 
of chronic MU have been reported, an emerging literature 
on the impact of chronic MU on the cardiovascular system 
has resulted in a growing recognition of methamphetamine-
associated cardiomyopathy and heart failure.6–9,12 Heart 
failure is a major public health problem in the US with an 
estimated prevalence of 5.2 million and direct and indirect 
costs totaling $33.2 billion.13 In addition to being one of the 
leading causes of hospitalization, disparities in the burden 
of heart failure have been identiﬁ  ed, with studies reporting 
poorer quality of life, more frequent hospitalizations, and 
decreased survival among African-Americans and Hispanics 
relative to Caucasians.14–16
Recent studies have found that a growing number 
of HF cases are being reported in patients with current 
or prior use of methamphetamine. Methamphetamine-
induced cardiomyopathy or HF seems to strike younger 
patients, racial/ethnic minorities and in some case reports, 
were found to be reversible.6, 8, 9, 12,17–19 Yeo and colleagues 
conducted a case-control study (N = 221) on heart failure 
patients admitted to a tertiary care hospital in Hawai’i and 
found that methamphetamine users (n = 107) had a 3.7-fold 
higher odds ratio for cardiomyopathy after adjustment for 
age, BMI, and renal failure.9 Other basic science studies also 
have suggested that methamphetamine exposure is associated 
with structural and functional changes of myocytes resulting 
in cardiomyopathy and the clinical syndrome of congestive 
heart failure.6,8,12,18,20–28
NHs and other PIPs are known to be at overall increased 
risk for heart disease as well as a number of risk factors for 
heart failure including diabetes, hypertension, tobacco use, 
and obesity13,14 and this population continues to experience 
disparities despite improvements in heart disease mortality 
experienced in the general US population.13,29 The purpose 
of this study is to examine socio-demographic and clinical 
risk factors associated with methamphetamine use in NHs 
and PIPs with moderate to severe heart failure.
Methods
Participants included in this study were enrolled in the 
Malama Pu’uwai (Heart Health Care) Study after informed 
consent was obtained. The Malama Pu’uwai Sudy (MPS) is a 
randomized controlled trial that is testing whether a culturally 
tailored educational program delivered post-discharge from 
the hospital will reduce re-hospitalization and/or mortality 
in NH and PIP patients with moderate to severe heart failure. 
All participants included in this study met the following 
eligibility criteria: 1) Self-identiﬁ  ed as Native Hawaiian 
and/or Paciﬁ  c Island racial/ethnic background (including 
Samoan, Tongan, Micronesian); 2) Age  21 years; 
3) Recently discharged from a single tertiary care hospital 
with a primary or secondary diagnosis of heart failure (index 
hospitalization); 4) moderate to severe heart failure deﬁ  ned 
as a left ventricular systolic ejection fraction (EF)  45% 
by echocardiography or similar cardiovascular imaging 
technique (eg, nuclear imaging, cardiac catheterization).
All participants underwent a baseline visit that included 
clinical assessment and a personal interview. Use of 
methamphetamine was determined by medical record review 
of the index hospitalization using a standardized protocol 
performed by a single trained reviewer or by a personal 
interview using standardized questionnaires at study entry. 
Positive methamphetamine use (MU) was deﬁ  ned as written 
documentation by a health care professional (eg, nurse, 
physician, social worker) or positive toxicology screen or 
if patient reported a history of methamphetamine use by 
interview. Participants without documentation of MU were 
categorized as non-methamphetamine users (non-MU) and 
served as the comparison group.
A total of 82 participants were enrolled between 
June 1, 2006 and December 31, 2007 in the MPS and were 
included in this study. All participants were interviewed 
and evaluated per the MPS protocol for: 1) demographics 
(ie, age, race/ethnicity – participants were allowed to self-
identify multiple race/ethnicity groups and then asked to 
select the group they identiﬁ  ed the most with, marital status 
and education); 2) assessment of alcohol consumption in 
the past 12 months (yes or no); and 3) smoked 100 or more 
cigarettes in their lifetime (yes or no); 4) Medication use, 
including prescription and/or non-prescription; 5) Clinical 
assessment of blood pressure, pulse, weight and measured 
height using standardized protocols. Medical records Vascular Health and Risk Management 2009:5 47
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from the index hospitalization also were reviewed for the 
following co-morbid conditions: 1) hypertension – deﬁ  ned 
as blood pressure  140/90 mmHg or known history of 
hypertension; 2) diabetes – deﬁ  ned as known history of 
diabetes by a medical professional; 3) atherosclerotic 
heart disease – deﬁ  ned as history of myocardial infarction, 
coronary bypass surgery or angioplasty or other percutaneous 
revascularization procedure; 4) history of cerebrovascular 
disease or stroke.
Statistics
Odds ratios were used to measure the association of risk 
factors between MU and non-MU and were computed 
using unconditional logistic regression.15 The 95% 
conﬁ  dence intervals for the OR estimates were determined 
using normal theory approximation. Signiﬁ  cance testing 
of regression coefﬁ  cients was based on Wald’s statistic. 
Any univariate factors associated with methamphetamine 
use was included into subsequent logistic regression 
modeling if the score statistic for that variable was statisti-
cally signiﬁ  cant after adjustment for multiplicity using the 
Hochberg procedure.16 The Fisher’s exact test was used for 
comparison of categorical variables and Student’s t-test for 
continuous variables. A p-value of  0.05 was considered to 
be statistically signiﬁ  cant. Statistical analysis was performed 
using SAS statistical software version 9.1.3 (SAS Institute, 
Cary, NC).
Results
Current or prior history of MU occurred in 22% of Native 
Hawaiians (NHs) and Pacific Island Peoples (PIPs) 
with moderate to severe heart failure. MUs were signiﬁ  cantly 
younger (mean age MU 43 years vs non-MU 58 years.; 
p =  0.0001), more likely to be NHs than PIPs and were more 
likely to be non-married (never married OR = 13, 95% CI, 
2.6–68; divorced/separated OR = 10, 95% CI, 1.7–62). MU 
was associated with higher BMI (BMI   30–39 kg/m2, 
OR 4.9; BMI   39 kg/m2, OR 3.9), higher pulse (OR 2.3–3.4), 
being a smoker (OR 2.9), an alcohol user (OR 2.2), or having 
a college degree (OR 2.8). However, none of these trends 
reached statistical signiﬁ  cance. No signiﬁ  cant differences (all 
odds ratios  1.9) were observed between MU and non-MU 
with regard to sex, or systolic or diastolic blood pressure 
(Tables 1 and 2).
Table 2 shows that the distribution of co-morbid 
conditions was similar between MU and non-MU. The 
most frequent co-morbid condition was hypertension (68%), 
followed by atherosclerotic heart disease (ASHD) at 62% and 
diabetes at 45%. The occurrence of ASHD was more frequent 
in the non-MU (67%) participants compared with the MU 
(44%), but was not statistically signiﬁ  cant. Overall, both the 
MU and the non-MU had an equal frequency of underlying 
co-morbid conditions despite the fact that the MU group was 
signiﬁ  cantly younger.
Using multiple logistic regression adjusting for all 
relevant variables, we found that older age ( 50 years 
old) was a ‘protective’ risk factor for MU (OR = 0.16, 
95% CI, 0.03–0.84) compared with non-MU. Non-married 
status (never married or divorced/separated) also was 
independently associated with an increased risk for MU 
(never married OR = 8.5, 95% CI, 1.5–47; divorced or 
separated OR = 11, 95% CI, 1.8–75) (Table 3). After 
adjustment for multiplicity, race/ethnicity was no longer a 
statistically signiﬁ  cant predictor of MU and consequently 
was not included in the multiple logistic regression model. 
Subsequent regression models were analyzed sequentially 
adding the following covariates: race/ethnicity, sex, educa-
tion, alcohol use, smoking, atherosclerotic heart disease, 
hypertension, diabetes, and stroke. However, none of these 
models changed the independent association of age and 
marital status with MU. Thus, we report in Table 3 the inde-
pendent association of younger age and non-married status 
with positive MU compared with non-MUs in a population 
of NHs and PIPs with moderate to severe HF.
Discussion
Methamphetamine use occurs frequently (22%) among NH 
and PIP patients with moderate to severe (LVEF   45%) heart 
failure. This ﬁ  nding adds to the growing clinical recognition of 
methamphetamine use in heart failure patients and in particular 
among high risk populations with cardiovascular disparities.30 
In a study by Yeo et al 43% of patients with cardiomyopathy 
were found to be MUs (prior or current users) and the majority 
of patients with cardiomyopathy and MU were NHs and PIPs 
(54%).9 Studies among primarily Caucasian patients also have 
reported nearly 20% of HF patients having a prior history of 
alcohol and/or substance abuse in addition to other co-morbid 
conditions, such as hypertension and diabetes.31 Our study is 
consistent with these ﬁ  ndings of more than 20% of patients 
with heart failure having MU as a contributing cause. In this 
high risk patient population, we found that methamphetamine 
users were signiﬁ  cantly more likely to be NHs compared with 
PIPs. Thus, although hypertension, ASHD, and diabetes are 
frequent underlying causes of HF, other potential cardiac 
insults such as methamphetamine use may pose additional 
cardiotoxicity.30Vascular Health and Risk Management 2009:5 48
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Table 1 Demographic characteristics of Native Hawaiian and Paciﬁ  c Island people with moderate to severe heart failure by 
methamphetamine use (N = 82)
Variable Positive methamphetamine 
use (n = 18) n (%)
Negative methamphetamine 
use (n = 64) n (%)
Odds ratio (95% CI)
Age
   40 years 6 (33) 6 (9) 1.0 Referent
  40–49 years 6 (33) 10 (16) 0.60 (0.13–2.7)
   50 years 6 (33) 48 (75) 0.13 (0.03–0.51)
Sex
  Female 4 (22) 22 (34) 1.0 Referent
  Male 14 (78) 42 (66) 1.8 (0.54–6.2)
Marital status
  Currently married 2 (11) 37 (58) 1.0 Referent
  Never 10 (56) 14 (22) 13 (2.6–68)
  Divorced or separated 5 (28) 9 (14) 10 (1.7–62)
  Widow or widower 1 (6) 4 (6) 4.6 (0.34–63)
Education level
  Less than high school 4 (22) 10 (16) 1.0 Referent
  High school diploma/GED 9 (50) 32 (51) 0.77 (0.20–3.0)
  Some college/technical training 2 (11) 18 (29) 0.31 (0.05–2.0)
  College degree 3 (17) 3 (5) 2.8 (0.39–20)
Race/Ethnicity
  Native Hawaiian 16 (89) 40 (63) 1.0 Referent
 Paciﬁ  c Island people 2 (11) 24 (38) 0.21 (0.04–.99)
Smoked 100 cigarettes in lifetime (%)
  No 2 (11) 17 (27) 1.0 Referent
  Yes 16 (89) 47 (73) 2.9 (0.60–14)
Alcohol consumed in past 12 months
  No 5 (28) 29 (45) 1.0 Referent
  Yes 13 (72) 35 (55) 2.2 (0.68–.8)
Our results also suggest that among racial/ethnic 
populations at high risk for cardiovascular disparities, 
such as heart failure, consideration of alterNative causes 
of HF may be important contributors to the manifestation 
of CVD disparities. Racial/ethnic differences in HF risk 
factors also was examined by Deswal et al in Black patients 
with advanced HF in a VA system.32 The authors found 
that uncontrolled hypertension and hospitalization for 
any cause accounted for a signiﬁ  cant difference in health 
disparities when compared with their White counterparts.32 
Similarly, our results suggest that the frequency or severity 
of known underlying causes of HF, such as MU in addition 
to a background of hypertension, ASHD and diabetes, may 
have a signiﬁ  cant additive effect on the development of CVD 
outcomes especially among NHs and PIPs. Surprisingly 
little is known about the prevalence of methamphetamine 
use in patients with heart failure. Yet it is well known that 
racial and ethnic minority patients have persistent disparities 
on the severity and treatment of heart failure that may 
contribute to differences in health outcomes. Miller recently 
highlighted the gap in our fund of knowledge between heart 
failure patients that have been included in clinical trials that 
guide practice guidelines and heart failure patients that are 
racially and demographically more diverse and for whom the 
treatment guidelines may not be optimal treatment. Thus, our 
studies provides new insight to the clinical and demographic 
characteristics of NHs and PIPs who are at increased risk for 
heart failure and for poor health outcomes.33
Our study is the ﬁ  rst to identify not only the increased 
frequency of MU among NH and PIP HF patients but also 
to examine the potential risk factors associated with MU in 
this distinct population. Although MU has been recognized 
as a growing health problem in the US since the early 1990s, 
little is available in the literature about its long term impact on Vascular Health and Risk Management 2009:5 49
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heart failure speciﬁ  cally and/or its impact on the development 
of cardiovascular disease in general.
A few studies have examined the differences in patient 
related factors among minority patients with heart failure 
compared with their white counter parts. Deswal et al found 
in a VA population that non-marital status was higher in 
Black patients with HF compared with Whites.32 Our study, 
in another high risk minority population, is in agreement with 
this study and others that suggests that greater awareness of 
psychosocial factors and MU in HF patients is needed and 
may have important implications for successful chronic 
disease management. In particular, programs aimed at 
treating and/or preventing HF hospitalizations and death in 
health disparate populations should consider the possibility 
of psychosocial issues (eg, marital status, social support) in 
patients with heart failure and a prior or current history of 
Table 2 Clinical characteristics among Native Hawaiian and Paciﬁ  c Island peoples with moderate – severe heart failure by methamphetamine 
use (N = 82)
Clinical characteristic Positive methamphetamine 
use (n = 18) n (%)
Negative methamphetamine 
use (n = 64) n (%)
Odds ratio (95% CI)
Blood pressure
  Systolic blood pressure*
   140 mmHg 16 (89) 60 (94) 1.0 Referent
   140 mmHg 2 (11) 4 (6) 1.9 (0.32–11)
Diastolic blood pressure*
   90 mmHg 16 (89) 59 (92) 1.0 Referent
   90 mmHg 2 (11) 5 (8) 1.5 (0.26–8.3)
Pulse*
   65 beats per minute 3 (17) 22 (34) 1.0 Referent
   65 to 85 beats per minute 9 (50) 29 (45) 2.3 (0.55–9.4)
   85 beats per minute 6 (33) 13 (20) 3.4 (0.72–16)
Body mass index
   30 kg/m2 2 (11) 22 (34) 1.0 Referent
   30 to 39 kg/m2 8 (44) 18 (28) 4.9 (0.92–26)
   39 kg/m2 6 (33) 17 (27) 3.9 (0.70–22)
  Unknown 2 (11) 7 (11) 3.1 (0.37–27)
Systolic Ejection Fraction, %
 Severe  ( 30) 11 (61) 36 (56) 1.0 Referent
  Moderate-severe (30–34) 1 (6) 7 (11) 0.47 (0.05–4.2)
  Moderate (35–39) 6 (33) 11 (17) 1.8 (0.54–5.9)
  Mild-Moderate (40–44) 0 (0) 10 (16) 0.16 (0.0088–3.0)†
Atherosclerotic Heart Disease
  No 10 (56) 21 (33) 1.0 Referent
  Yes 8 (44) 43 (67) 0.39 (0.14–1.1)
Stroke*
  No 16 (89) 58 (91) 1.0 Referent
  Yes 2 (11) 6 (9) 1.2 (.22–6.6)
Diabetes mellitus*
  No 10 (56) 35 (55) 1.0 Referent
  Yes 8 (44) 29 (45) 0.97 (0.34–2.8)
Hypertensiona*
  No 5 (28) 21 (33) 1.0 Referent
  Yes 13 (72) 43 (67) 1.3 (0.40–4.0)
*Missing values ( 2) were absorbed into the referent groups.
†Missing cell imputed with 0.5 in order to compute OR and CI.Vascular Health and Risk Management 2009:5 50
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MU as they relate to successful heart failure management. 
Speciﬁ  cally, patients with HF that have a prior history of 
MU may be younger than the typical HF patient and may 
have a need for alterNative approaches to ensure adherence 
to the treatment regimen.
Other studies have examined the role of marital status 
on health outcomes in HF patients. One study found that 
among HF patients that were married, the quality of this 
relationship independently predicted survival, especially 
among women HF patients.34 Another study found that high 
social networking, irrespective of marital status, reduced 
re-hospitalization in HF patients.35 Our results support the 
‘protective’ role of being married on the association of MU 
in HF patients. The mechanism for how being married may 
‘protect’ against MU has been proposed to be via social 
support that may mitigate the risk for illicit drug use. 
This proposed mechanism is supported by other studies in 
which patients with heart failure who were unmarried had 
a lower level of self-care knowledge and adherence than 
those who were married, indicating that marriage improves 
the ability to care for one’s self.36 The long term beneﬁ  ts of 
social support in HF patients is consistent with a wealth of 
literature that has reported that improved health status and 
social support are associated with decreased hospitalizations 
or all cause death.37
Unfortunately, the cross sectional design of our study 
does not allow for determining cause and effect relation-
ships between marital status and MU in HF patients. 
However, recognition of MU in HF patients is important 
not only for diagnostic purposes but also for long term 
treatment and prevention of HF in patients from minority or 
health disparate populations. Further delineation of which 
factors (ie, hypertension, diabetes, methamphetamine, etc.) 
either collectively or individually can be attributed to the 
development of heart failure in this population will aid 
our understanding in developing appropriate treatments to 
reverse these trends. Our study also highlights an opportu-
nity to intervene early to prevent advanced heart failure in 
NH and PIP patients with a prior history of MU who may 
beneﬁ  t from programs that can provide a supportive context 
to prevent relapse of MU as well as HF disease manage-
ment. Further understanding as to the underlying risk factors 
leading to HF are needed in health disparity populations. 
Innovative approaches to reduce and/or prevent the devel-
opment of advanced HF in these populations has important 
social and economic implications for the health burden of 
HF in the US since HF is one of the most costly disease 
hospitalizations in the US.38,39
Several limitations should be considered when interpreting 
the results of this study. The cross-sectional design precludes 
making any causal inferences between the model risk factors 
and MU. While the limited sample size may be contributing to 
the lack of statistical signiﬁ  cance observed for some of the risk 
factors examined. Medical record review of methamphetamine 
use may also underestimate the actual number of metham-
phetamine users and other illicit drugs such as cocaine were 
not assessed in this study. Despite these limitations, this study 
provides initial ﬁ  ndings to a growing body of literature that is 
recognizing with greater frequency the role of methamphet-
amine use as a signiﬁ  cant contributor to the development of HF. 
Because MU and heart failure tends to occur more frequently 
in racial and ethnic minority populations and originally became 
manifest in the western regions of the US where the majority 
of NHs and PIPs reside. This may be, just the beginning of a 
larger, but as of yet unrecognized, problem that contributes to 
the management of heart failure and cardiomyopathy especially 
in high risk minority or ethnic populations.
Our study suggests that MU in NHs and PIPs with 
moderate to severe heart failure occurs at a frequency of more 
than 1 in 5 cases (22%). Factors independently associated 
with MU in heart failure patients of NHs and PIP ancestry 
were non-marital status and younger age. Intervention 
efforts to reduce persistent cardiovascular health disparities, 
speciﬁ  cally heart failure, may want to consider strategies to 
also reduce MU in this and other high risk patients. Further 
studies are needed to identify key modiﬁ  able risk factors 
that may enable better health outcomes in health disparate 
populations (eg, NHs and other PIPs) if we hope to reverse 
and eventually eliminate heart failure disparities.
Table 3 Multivariate analysis of factors associated with 
methamphetamine use in Native Hawaiians and Paciﬁ  c Island 
peoples with moderate to severe heart failure (N = 82)*
Factors Odds ratio (95% CI)
Age (years)
   40 1.0 Referent
   40 to 50 0.70 (0.13–3.9)
   50 0.16 (0.03–0.84)
Marital status
  Currently married 1.0 Referent
 Never  married 8.5  (1.5–47)
  Divorced or separated 11 (1.8–75)
  Widow or widower 5.7 (0.38–87)
*Adjustment for race/ethnicity, sex, education, alcohol use, smoking, atherosclerotic 
heart disease, stroke, hypertension, and diabetes were not signiﬁ  cant confounders 
to the model.Vascular Health and Risk Management 2009:5 51
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